IMMUNOGLOBULINS
Sponsors
Alexion Pharmaceuticals Inc., Assistance Publique Hopitaux De Paris, Janssen Cilag International, Toleranzia AB, Nuvig Therapeutics Inc.
Conditions
Acquired Immunodeficiency SyndromeAdult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestationsBlood TransfusionCIDPCOVID-19COVID-19
COVID-19
SARS-CoV2Chronic Inflammatory Demyelinating PolyneuropathyCytomegalovirus Infections
Phase 1
Dose scale-up and cohort expansion with the therapeutic mAb 14F7
Active, not recruitingRPCEC00000204
Start: 2016-01-01Target: 60Updated: 2026-08-10
Anti SARS-CoV-2 gammaglobulin
Active, not recruitingRPCEC00000379
Start: 2021-07-01Target: 30Updated: 2026-08-10
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
Not yet recruitingCTIS2024-515627-10-00
Target: 42Updated: 2025-02-12
Phase 2
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingNCT04881682
Start: 2023-05-01End: 2028-03-01Target: 20Updated: 2026-05-01
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
RecruitingNCT05678621
Start: 2022-11-30End: 2027-04-30Target: 300Updated: 2024-04-19
Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment
RecruitingNCT06159283
Start: 2024-03-18End: 2025-12-31Target: 58Updated: 2024-05-16
Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM study)
Not yet recruitingCTIS2023-506599-28-01
Target: 120Updated: 2025-01-09
An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia
RecruitingCTIS2024-520359-26-00
Start: 2025-08-20Target: 25Updated: 2025-09-04
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of
Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in
Participants With Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2025-524793-42-00
Target: 81Updated: 2026-08-26
Phase 3
Transfusion-Transmitted Cytomegalovirus Prevention in Neonates
CompletedNCT00000584
Start: 1983-07-31End: 1988-06-30Updated: 2013-11-26
Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
CompletedNCT00000590
Start: 1991-09-30End: 1996-12-31Updated: 2016-04-14
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX)
RecruitingCTIS2024-516403-16-00
Start: 2022-04-07Target: 272Updated: 2025-05-27
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
RecruitingCTIS2023-509434-19-00
Start: 2025-02-10Target: 13Updated: 2026-01-21
PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma
Not yet recruitingCTIS2025-521571-30-00
Target: 228Updated: 2026-04-13